-
公开(公告)号：CA2907349A1
公开(公告)日：2014-09-18
申请号：CA2907349
申请日：2014-03-15
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , EISENBUD DAVID , BANNAN SCOTT , POOL DAVID , MATSUOKA GROVE , SUNDERLAND TRACEY , DUFT BRADFORD
Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
-
公开(公告)号：CA2940648A1
公开(公告)日：2015-09-03
申请号：CA2940648
申请日：2015-02-25
Applicant: CODA THERAPEUTICS INC
Inventor： BANNAN SCOTT , MATSUOKA GROVE , DUFT BRADFORD , PHILLIPS ANTHONY , EISENBUD DAVID
Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.
-
Patent Agency Ranking
公开(公告)号：AU2014233101A1
公开(公告)日：2015-10-15
申请号：AU2014233101
申请日：2014-03-15
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , EISENBUD DAVID , BANNAN SCOTT , POOL DAVID , MATSUOKA GROVE , SUNDERLAND TRACEY , DUFT BRADFORD
Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
-
公开(公告)号：WO2014145342A3
公开(公告)日：2014-12-31
申请号：PCT/US2014030082
申请日：2014-03-15
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , EISENBUD DAVID , BANNAN SCOTT , POOL DAVID , MATSUOKA GROVE , SUNDERLAND TRACEY , DUFT BRADFORD
CPC classification number: A61K31/7088 , A61B5/0064 , A61B5/0077 , A61B5/1072 , A61B5/1079 , A61B5/1109 , A61B5/445 , A61B5/4839 , A61B5/4848 , A61B5/7275 , A61B2503/40 , A61K9/0014 , A61K9/06 , A61K9/70 , A61K31/7105 , A61K47/00 , A61K47/10 , A61K47/38 , A61K48/00 , C07K14/47 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12N2320/35
Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。
-
公开(公告)号：WO2015130840A3
公开(公告)日：2015-11-05
申请号：PCT/US2015017595
申请日：2015-02-25
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , BANNAN SCOTT , MATSUOKA GROVE , DUFT BRADFORD , EISENBUD DAVID
CPC classification number: C12N15/113 , C12N2310/11
Abstract: Connexin protein modulation methods and compositions are provided for the healing of resistant lesions, including lesions on subjects with multiple venous leg ulcers or multiple diabetic foot ulcers, and other responder subjects. Also provided are kits and articles of manufacture comprising a connexin protein modulating agent, for example, a connexin 43 modulating agent for use in the healing of resistant lesions.
Abstract translation: 提供连接蛋白调节方法和组合物用于治愈耐药性病变，包括具有多个静脉性腿溃疡或多发性糖尿病足溃疡的受试者和其他响应者受试者的损伤。 还提供了包含连接蛋白调节剂（例如连接蛋白43调节剂）的试剂盒和制品，用于治愈抵抗性病变。
-
公开(公告)号：EP3110455A4
公开(公告)日：2017-10-11
申请号：EP15755058
申请日：2015-02-25
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , BANNAN SCOTT , MATSUOKA GROVE , DUFT BRADFORD
CPC classification number: C12N15/113 , C12N2310/11
-
公开(公告)号：EP2970967A4
公开(公告)日：2017-04-26
申请号：EP14764924
申请日：2014-03-15
Applicant: CODA THERAPEUTICS INC
Inventor： PHILLIPS ANTHONY , EISENBUD DAVID , BANNAN SCOTT , POOL DAVID , MATSUOKA GROVE , SUNDERLAND TRACEY , DUFT BRADFORD
IPC: C12N15/113 , A61K31/7088
CPC classification number: A61K31/7088 , A61B5/0064 , A61B5/0077 , A61B5/1072 , A61B5/1079 , A61B5/1109 , A61B5/445 , A61B5/4839 , A61B5/4848 , A61B5/7275 , A61B2503/40 , A61K9/0014 , A61K9/06 , A61K9/70 , A61K31/7105 , A61K47/00 , A61K47/10 , A61K47/38 , A61K48/00 , C07K14/47 , C12N15/1138 , C12N2310/11 , C12N2310/14 , C12N2320/30 , C12N2320/35
Abstract: This invention concerns improved methods, uses, and kits for treating chronic wounds through the administration of anti-connexin agents, particularly anti-connexin 43 antisense polynucleotides. The methods, uses, and kits of the invention are based on the surprising and unexpected discovery that chronic wounds that do not increase or decrease in size by more than a pre-determined amount during a pre-treatment phase are more amenable to successful treatment than wounds whose size varies outside the target range during the pre-treatment phase.
Abstract translation: 本发明涉及通过施用抗连接蛋白剂，特别是抗连接蛋白43反义多核苷酸治疗慢性伤口的改进的方法，用途和试剂盒。 本发明的方法，用途和试剂盒基于惊人的和意想不到的发现，即在预处理阶段期间，不增加或减少大小超过预定量的慢性伤口比成功治疗更适合于比 在预处理阶段，其大小在目标范围之外变化的伤口。
-
-
-
-
-
-
Search Results
7
records
(took 0.02 seconds)
